When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...

Learn about HER2+ breast cancer, its aggressive nature, and the latest treatments available in India. Explore the impact of ...

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ...

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely ...

Claudine Isaacs, MD: For this patient who's progressed after more than 12 months with an ESR1 mutation and HER2-low disease ...

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu as a second-line therapy for HER2-positive metastatic breast ...

Scientists have developed compounds that selectively block a crucial interaction between RAS and the enzyme PI3K, a driver of tumor growth. Scientists from the Francis Crick Institute and Vividion The ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS, and a key ...